Exelixis raises $71.8 million through stock offering

South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.

Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Mental health, suicide hotlines brace for surge of crisis calls

Responders feel the weight of the coronavirus-related calls themselves

SFUSD reduces food pick-up days, sites

The district will still provide five days worth of meals for children

In a time of isolation, the demand for animal companions has increased

Flooded with requests to foster or adopt, shelters and rescue groups move operations online

San Francisco sees fifth coronavirus death, 340 cases

Mobile testing sites will be expanded to Sunset, Chinatown this week

Chinatown SRO tenants fear close quarters will spread coronavirus

Shared kitchens, bathrooms make it difficult to avoid contagion

Most Read